{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:11:28Z","timestamp":1778663488454,"version":"3.51.4"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005145","name":"Basic Research Program of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20251750"],"award-info":[{"award-number":["BK20251750"]}],"id":[{"id":"10.13039\/501100005145","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005145","name":"Basic Research Program of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20231141"],"award-info":[{"award-number":["BK20231141"]}],"id":[{"id":"10.13039\/501100005145","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32371434"],"award-info":[{"award-number":["32371434"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010014","name":"Six Talent Peaks Project in Jiangsu Province","doi-asserted-by":"publisher","award":["WSN-082"],"award-info":[{"award-number":["WSN-082"]}],"id":[{"id":"10.13039\/501100010014","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bioorg.2026.109625","type":"journal-article","created":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T22:52:17Z","timestamp":1770591137000},"page":"109625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["PET imaging of XPO1 engagement with [18F]selinexor: A pharmacodynamic theranostic strategy for multiple myeloma"],"prefix":"10.1016","volume":"173","author":[{"given":"Xinlin","family":"Zhong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghui","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongyang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bioorg.2026.109625_bb0005","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109625_bb0010","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3390\/cancers16051033","article-title":"Role of non-coding RNAs in diagnosis, prediction and prognosis of multiple myeloma","volume":"16","author":"Dubaj","year":"2024","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.bioorg.2026.109625_bb0015","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41568-024-00755-x","article-title":"New horizons in our understanding of precursor multiple myeloma and early interception","volume":"24","author":"Cordas dos Santos","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109625_bb0020","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109625_bb0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin. Proc."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109625_bb0030","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109625_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-08280-y","article-title":"Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Cancer"},{"issue":"23","key":"10.1016\/j.bioorg.2026.109625_bb0040","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1158\/0008-5472.CAN-19-0677","article-title":"Melphalan and exportin 1 inhibitors exert synergistic antitumor effects in preclinical models of human multiple myeloma","volume":"80","author":"Turner","year":"2020","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.bioorg.2026.109625_bb0045","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.bioorg.2026.109625_bb0050","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1182\/blood-2018-06-858852","article-title":"Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma","volume":"132","author":"Bahlis","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109625_bb0055","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109625_bb0060","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/leu.2013.115","article-title":"CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications","volume":"28","author":"Tai","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.109625_bb0065","first-page":"169","article-title":"Novel approaches to treating relapsed and refractory multiple myeloma with a focus on recent approvals of belantamab mafodotin and selinexor","volume":"13","author":"Joseph","year":"2021","journal-title":"Clin. Pharm."},{"issue":"12","key":"10.1016\/j.bioorg.2026.109625_bb0070","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/leu.2013.172","article-title":"Genome-wide studies in multiple myeloma identify XPO1\/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276","volume":"27","author":"Schmidt","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109625_bb0075","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","article-title":"The nuclear export protein XPO1\u2014from biology to targeted therapy","volume":"18","author":"Azmi","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109625_bb0080","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0092-8674(00)80370-0","article-title":"Exportin 1 (Crm1p) is an essential nuclear export factor","volume":"90","author":"Stade","year":"1997","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bioorg.2026.109625_bb0085","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/1060028019892643","article-title":"Selinexor: a first-in-class nuclear export inhibitor for management of multiply relapsed multiple myeloma","volume":"54","author":"Peterson","year":"2020","journal-title":"Ann. Pharmacother."},{"issue":"8","key":"10.1016\/j.bioorg.2026.109625_bb0090","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40262-021-01016-y","article-title":"Pharmacokinetics of selinexor: the first-in-class selective inhibitor of nuclear export","volume":"60","author":"Bader","year":"2021","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109625_bb0095","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1158\/2159-8290.CD-13-1005","article-title":"Promising SINEs for embargoing nuclear\u2013cytoplasmic export as an anticancer strategy","volume":"4","author":"Tan","year":"2014","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109625_bb0100","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/s41589-024-01586-5","article-title":"Targeting the chromatin binding of exportin-1 disrupts NFAT and T cell activation","volume":"20","author":"Chen","year":"2024","journal-title":"Nat. Chem. Biol."},{"issue":"12","key":"10.1016\/j.bioorg.2026.109625_bb0105","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J."},{"issue":"13","key":"10.1016\/j.bioorg.2026.109625_bb0110","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s40265-019-01188-9","article-title":"Selinexor: first global approval","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109625_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040620720930629","article-title":"Selinexor in relapsed\/refractory multiple myeloma","volume":"11","author":"Richter","year":"2020","journal-title":"Ther. Adv. Hematol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109625_bb0120","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00259-023-06485-w","article-title":"STING-targeted PET tracer for early assessment of tumor immunogenicity in colorectal cancer after chemotherapy","volume":"51","author":"Xu","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109625_bb0125","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","article-title":"Immunogenic cell stress and death","volume":"23","author":"Kroemer","year":"2022","journal-title":"Nat. Immunol."},{"issue":"21","key":"10.1016\/j.bioorg.2026.109625_bb0130","doi-asserted-by":"crossref","first-page":"6498","DOI":"10.1158\/1078-0432.CCR-17-0664","article-title":"89Zr-anti-\u03b3H2AX-TAT but not 18F-FDG allows early monitoring of response to chemotherapy in a mouse model of pancreatic ductal adenocarcinoma","volume":"23","author":"Knight","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109625_bb0135","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.7150\/thno.20491","article-title":"11C-methionine-PET in multiple myeloma: a combined study from two different institutions","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"issue":"12","key":"10.1016\/j.bioorg.2026.109625_bb0140","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2967\/jnumed.112.106500","article-title":"Metabolic tumor volume assessed by 18F-FDG PET\/CT for the prediction of outcome in patients with multiple myeloma","volume":"53","author":"Fonti","year":"2012","journal-title":"J. Nucl. Med."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109625_bb0145","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s11307-022-01734-0","article-title":"Comparison of [18F]fluciclovine and [18F]FDG PET\/CT in newly diagnosed multiple myeloma patients","volume":"24","author":"Stokke","year":"2022","journal-title":"Mol. Imaging Biol."},{"issue":"7","key":"10.1016\/j.bioorg.2026.109625_bb0150","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1007\/s00259-024-06621-0","article-title":"[68Ga]Pentixafor PET\/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [18F]FDG PET\/CT","volume":"51","author":"Chen","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"25","key":"10.1016\/j.bioorg.2026.109625_bb0155","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"Moreau","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109625_bb0160","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low expression of hexokinase-2 is associated with false-negative FDG\u2013positron emission tomography in multiple myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109625_bb0165","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the international myeloma working group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.bioorg.2026.109625_bb0170","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1007\/s00259-023-06214-3","article-title":"Head-to-head comparison of [68Ga]ga-PSMA-11 and [18F] FDG PET\/CT in multiple myeloma","volume":"50","author":"Souza","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109625_bb0175","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3390\/jcm13010264","article-title":"Imaging of multiple myeloma: present and future","volume":"13","author":"Rodriguez-Laval","year":"2024","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109625_bb0180","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109625_bb0185","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7150\/thno.13921","article-title":"11C-methionine-PET in multiple myeloma: correlation with clinical parameters and bone marrow involvement","volume":"6","author":"Lapa","year":"2016","journal-title":"Theranostics"},{"issue":"8","key":"10.1016\/j.bioorg.2026.109625_bb0190","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1021\/acs.bioconjchem.5c00374","article-title":"Exploring 18F\/19F isotopic exchange for the synthesis of [18F]trifluoromethylated arenes","volume":"36","author":"Zhong","year":"2025","journal-title":"Bioconjug. Chem."},{"issue":"7607","key":"10.1016\/j.bioorg.2026.109625_bb0195","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nature17667","article-title":"Concerted nucleophilic aromatic substitution with 19F\u2212 and 18F\u2212","volume":"534","author":"Neumann","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109625_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116996","article-title":"Hetero-aryl bromide precursor fluorine-18 radiosynthesis and preclinical evaluation of a novel positron emission tomography (PET) tracer [18F]GSK1482160","volume":"73","author":"Huang","year":"2022","journal-title":"Bioorg. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2026.109625_bb0205","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1021\/acs.molpharmaceut.4c00137","article-title":"Synthesis and characterization of a novel PET tracer for noninvasive evaluation of FGL1 status in tumors","volume":"21","author":"Tan","year":"2024","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.bioorg.2026.109625_bb0210","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1007\/s00259-025-07107-3","article-title":"Development and biological evaluation of a novel CEACAM6-targeted PET tracer for distinguishing malignant nodules in early-stage lung adenocarcinoma","volume":"52","author":"Zhu","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.109625_bb0215","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1038\/s41467-018-07764-z","article-title":"Effective weight control via an implanted self-powered vagus nerve stimulation device","volume":"9","author":"Yao","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109625_bb0220","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13075-020-2145-y","article-title":"MiR-21-5p regulates extracellular matrix degradation and angiogenesis in TMJOA by targeting Spry1","volume":"22","author":"Ma","year":"2020","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109625_bb0225","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jfluchem.2010.10.008","article-title":"N-(4-(di-tert-butyl[18F]fluorosilyl)benzyl)-2-hydroxy-N,N-dimethylethylammonium bromide ([18F]SiFAN+Br\u2212): a novel lead compound for the development of hydrophilic SiFA-based prosthetic groups for 18F-labeling","volume":"132","author":"Kostikov","year":"2011","journal-title":"J. Fluor. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109625_bb0230","doi-asserted-by":"crossref","first-page":"472","DOI":"10.7150\/thno.79452","article-title":"Simplified one-pot 18F-labeling of biomolecules with in situ generated fluorothiophosphate synthons in high molar activity","volume":"13","author":"Yang","year":"2023","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109625_bb0235","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/neuonc\/nou303","article-title":"Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma","volume":"17","author":"Green","year":"2015","journal-title":"Neuro-Oncology"},{"issue":"24","key":"10.1016\/j.bioorg.2026.109625_bb0240","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2016-11-750158","article-title":"A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia","volume":"129","author":"Garzon","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109625_bb0245","doi-asserted-by":"crossref","DOI":"10.1038\/srep16077","article-title":"Targeting the nuclear export protein XPO1\/CRM1 reverses epithelial to mesenchymal transition","volume":"5","author":"Azmi","year":"2015","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109625_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary multiple myeloma","volume":"34","author":"Bhutani","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.109625_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2023.116957","article-title":"The role of conventional and novel PET radiotracers in assessment of myeloma bone disease","volume":"179","author":"Zirakchian Zadeh","year":"2024","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.bioorg.2026.109625_bb0260","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jtho.2019.05.032","article-title":"Positron-emission tomographic imaging of a fluorine 18\u2013radiolabeled poly (ADP-ribose) polymerase 1 inhibitor monitors the therapeutic efficacy of talazoparib in SCLC patient\u2013derived xenografts","volume":"14","author":"Laird","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109625_bb0265","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1158\/1078-0432.CCR-23-2130","article-title":"CD46-targeted theranostics for PET and 225Ac-radiopharmaceutical therapy of multiple myeloma","volume":"30","author":"Wadhwa","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109625_bb0270","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00259-024-07036-7","article-title":"CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies","volume":"52","author":"Huang","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826001616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826001616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:32:01Z","timestamp":1778661121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826001616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":54,"alternative-id":["S0045206826001616"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109625","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PET imaging of XPO1 engagement with [18F]selinexor: A pharmacodynamic theranostic strategy for multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109625","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109625"}}